Logan Reed
Tuberculosis (TB) is a contagious bacterial infection that affects the lungs and other parts of the body. While there is a vaccine for TB, known as the bacille Calmette-Guérin (BCG) vaccine, it is not commonly used in the United States. The decision not to routinely use the vaccine is due to a combination of factors, including the low risk of contracting TB in the US, the variable effectiveness of the vaccine, and the potential interference with tuberculin skin tests used to detect TB infections. However, the BCG vaccine may still be recommended for certain high-risk individuals, such as children frequently exposed to TB or healthcare professionals working in high-risk settings.
| Characteristics | Values |
|---|---|
| Name of the vaccine | Bacille Calmette-Guérin (BCG) |
| Who is it recommended for? | The BCG vaccine is not recommended for the general population in the US. It is only recommended for children living with someone with TB who cannot take antibiotics or are infected with a strain resistant to antibiotics. It is also recommended for healthcare professionals working in areas with a high percentage of people with TB. |
| How is it administered? | The vaccine is given as a shot in the upper arm or skin. |
| Effectiveness | The BCG vaccine is effective at preventing disseminated disease in infants but confers variable efficacy against pulmonary TB in adults. The vaccine's protection weakens over time. |
| Side effects | Serious side effects are rare. Redness, swelling, mild pain, and a small ulcer may occur at the injection site. |
Explore related products
What You'll Learn
The BCG vaccine is not widely used in the US
The Bacille Calmette-Guérin (BCG) vaccine is a vaccine for tuberculosis (TB) disease. It is made from a weakened form of the bacterium Mycobacterium bovis, which causes a TB-like illness in cattle. While the vaccine is safe, evidence of its effectiveness in protecting against TB is mixed.
The BCG vaccine is most effective in babies and young children, protecting them from getting severe forms of active TB disease, such as TB meningitis. However, its effectiveness in adults is variable, with some studies showing a range of effectiveness from zero to 80%. The protection offered by the vaccine also weakens over time, with one study showing protection waning to 59% after 15 years and disappearing after 20 years.
In the US, the BCG vaccine is only recommended for a small subset of people with significant risk factors for prolonged exposure to TB. This includes children living with someone who has TB and cannot take antibiotics or is infected with a drug-resistant strain. The decision to vaccinate is typically made in consultation with a local TB control program or a doctor experienced in TB.
While the BCG vaccine is not widely used in the US, it is still given to infants and young children in many countries where TB is more common.
Vaccination Policy: A Collective Action Problem
You may want to see also
Explore related products
$157.54 $159
The vaccine is only recommended for high-risk groups
The Bacille Calmette-Guérin (BCG) vaccine is available for tuberculosis (TB) and is used in many countries worldwide. However, it is not routinely given in the United States and is not recommended for the general population. The BCG vaccine is specifically recommended for high-risk groups who are more likely to be exposed to TB or have a higher risk of severe disease.
TB is caused by the bacterium Mycobacterium tuberculosis, which usually attacks the lungs but can affect other parts of the body. It is a contagious infection that can be transmitted from person to person. While TB is a serious health concern globally, the risk of contracting it in the United States is relatively low.
The BCG vaccine is most effective in infants and young children, offering protection against severe forms of TB such as TB meningitis and disseminated TB. In countries where TB is prevalent, the vaccine is routinely administered to newborns and young children, providing up to 80% protection against these severe types of TB. However, the protection weakens over time, and the vaccine's effectiveness in adults is more variable.
In the United States, the BCG vaccine may be recommended for certain high-risk groups, including children who are frequently exposed to TB or live with someone infected with a strain of TB that is resistant to antibiotics. Additionally, healthcare professionals working in areas with a high prevalence of TB or ongoing transmission may also be considered for the vaccine.
While the BCG vaccine has been shown to provide some protection against TB, its effectiveness varies across different populations and age groups. Recent studies suggest that the vaccine is only significantly effective in preventing severe disease in children under five years old. The variable efficacy of the BCG vaccine has been a subject of ongoing research, with efforts focused on improving vaccine design and understanding its interaction with the immune system.
Vaccine Refusal: Options for Employers and Employees
You may want to see also
Explore related products
Tuberculosis is no longer common in the US
Tuberculosis (TB) is a contagious bacterial infection caused by the Mycobacterium tuberculosis bacterium. It typically affects the lungs, causing pulmonary TB, but it can also affect other parts of the body, such as the spine, brain, or kidneys. While TB was once a significant health concern in the United States, its incidence has been steadily declining over the past few decades. This decline is likely due to improved medical treatments and better control of HIV with the use of anti-retroviral drugs.
The Bacille Calmette-Guérin (BCG) vaccine is a live vaccine developed in the early 1900s to protect against TB. It is created from a weakened strain of Mycobacterium bovis, a bacterium closely related to the one that causes TB in humans. While the BCG vaccine is routinely used in many countries to protect infants and young children from severe forms of TB, it is not commonly administered in the United States. The main reasons for its limited use in the US include:
- The low risk of contracting TB in the United States due to improved medical treatments and better disease control.
- Variable effectiveness of the BCG vaccine in preventing TB, especially in adults and older children. Studies have shown that the vaccine's protection weakens over time and may not be effective after 20 years.
- The possibility of the BCG vaccine interfering with tuberculin skin tests used to detect TB infections, leading to false positives.
In the United States, the BCG vaccine is only recommended for specific high-risk groups, such as children frequently exposed to TB or healthcare professionals working in high-risk settings. However, even within these groups, the decision to vaccinate is made on a case-by-case basis, considering the individual's specific risk factors and exposure.
While the BCG vaccine has played a role in controlling TB infections, particularly in high-incidence regions, there is an ongoing need for more effective vaccines. Research efforts are currently focused on understanding the complex interaction between M.tb and the human immune system to design more potent vaccines.
Blue Cross Blue Shield Illinois: Understanding Your Vaccine Coverage
You may want to see also
Explore related products
The vaccine is more effective in children under 5
The Bacille Calmette-Guérin (BCG) vaccine is a vaccine for tuberculosis (TB) that is not routinely given in the United States. The vaccine is generally recommended for children under 5 in countries where TB is common, as it protects them from severe forms of TB such as TB meningitis. However, its effectiveness in preventing pulmonary TB is variable and decreases over time.
The BCG vaccine is not widely used in the United States due to the low risk of contracting TB in the country and the variable effectiveness of the vaccine in preventing TB in adults. The vaccine is only recommended for a small subset of individuals who are in constant contact with someone infected with a strain of TB that is resistant to antibiotics. This recommendation is typically made in consultation with a local TB control program.
While the BCG vaccine has been shown to reduce infections and the progression to active TB, its effectiveness is higher in preventing severe forms of TB in children under 5. The vaccine's protection weakens over time, and it may not be as effective in older children and adults. Recent research suggests that the BCG vaccine only provides significant protection against any type of TB in children under 5.
The BCG vaccine is safe and has been thoroughly tested and vetted for safety. It is given as a shot in the upper arm or injected into the skin, usually to infants just after birth. While soreness and mild side effects, such as redness, swelling, and pain at the injection site, are common, serious side effects are rare.
The BCG vaccine is one of the only licensed vaccines against TB and has been shown to be effective in preventing disseminated disease in infants. However, its efficacy in preventing pulmonary TB in adults, especially in the developing world, is highly variable. The variable efficacy of the BCG vaccine may be due to factors such as the BCG strain and previous exposure to environmental mycobacteria.
Blue Cross Blue Shield Texas: Vaccines Covered
You may want to see also
Explore related products
The vaccine has variable efficacy in different countries
The Bacille Calmette-Guérin (BCG) vaccine is the only licensed vaccine for tuberculosis (TB). It is made from a weakened form of the bacterium Mycobacterium bovis, which causes a TB-like illness in cattle. The BCG vaccine is safe, but its effectiveness in protecting against TB is mixed.
The BCG vaccine is not widely used in the United States, and it is not recommended for the general population. This is partly due to the low risk of contracting TB in the US. However, the BCG vaccine may be considered for children and adults with a high risk of tuberculosis exposure, such as those in constant contact with an infected person.
The BCG vaccine is more commonly used in other countries, particularly where TB is more prevalent. It is mainly used to protect against severe forms of TB in infants and young children, such as TB meningitis and disseminated TB, and is typically given just after birth. In these cases, the BCG vaccine has been found to provide up to 80% protection. However, this protection weakens over time and is less effective in older children and adults.
The efficacy of the BCG vaccine varies depending on the geographical location. For example, trials in the UK consistently show a 60 to 80% protective effect, while trials conducted elsewhere have shown no protective effect. The closer one gets to the equator, the lower the efficacy of the vaccine appears to be. This variation in efficacy may be due to factors such as BCG strain and previous exposure to environmental mycobacteria.
The End of Polio Sugar Cubes
You may want to see also
Frequently asked questions
Yes, the vaccine for tuberculosis is called the bacille Calmette-Guérin (BCG) vaccine.
The BCG vaccine is not routinely given in the US and is not recommended for the general population. However, it may be considered for children and adults with a high risk of tuberculosis exposure.
The BCG vaccine is a live vaccine that uses a weakened strain of Mycobacterium bovis, a bacterium closely related to the one that causes TB. It is injected into the skin or upper arm and has been shown to be safe, although its effectiveness varies.
